Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Naves, R.
Right arrow Articles by Bono, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naves, R.
Right arrow Articles by Bono, M. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 14, No. 5, pp. 481-491, May 2002
© 2002 Japanese Society for Immunology

MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator

Rodrigo Naves1, Ana Maria Lennon2, Giovanna Barbieri3,4, Lilian Reyes1, Gisella Puga1, Laura Salas2, Virginie Deffrennes3, Mario Rosemblatt1, Marc Fellous2, Dominique Charron3, Catherine Alcaïde-Loridan3 and Maria Rosa Bono1

1 Departamento de Biologia, Facultad de Ciencias, Universidad de Chile, and Millennium Institute for Fundamental and Applied Biology, Casilla 653, Santiago, Chile 2 Unité d‘Immunogénétique Humaine, INSERM U276, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris Cedex 15, France 3 INSERM U396, Centre de Recherches Biomédicales des Cordeliers, 15 rue de l‘Ecole de Médecine, 75006 Paris, France 4 Permanent address: Istituto di Biologia dello Sviluppo, CNR 152 via Ugo La Malfa, 90146 Palermo, Italy

The first two authors contributed equally to this work
Correspondence to: M. R. Bono; E-mail: mrbono{at}uchile.cl
Transmitting editor: D. R. Littman

MHC class II expression defects have been evidenced in several human tumor cell lines originating from lung cancers or retinoblastoma. Accordingly, the mouse adenocarcinoma and fibrosarcoma cell lines, RAG and L(tk), do not express I-A and I-E molecules even when treated with IFN-{gamma}. Here we show that fusion of both cell lines restores the inducible expression of MHC class II, thereby demonstrating that they present different and recessive alterations outside the MHC class II locus. CIITA, the MHC class II transactivator, controls the tissue-specific expression of MHC class II genes and creates the architecture of the transcriptional complex that binds to the MHC class II gene promoters. In L(tk) cells, C2ta transcripts, expressed from the gene encoding CIITA, were indeed detected in severely limited amounts, with a defect in C2ta transcription initiation. In agreement we show here that the L(tk) cell line does not express the CIITA protein. In contrast, in the RAG cell line, C2ta transcripts were expressed at normal levels, from the proper initiation site. The nucleotide sequencing of the CIITA cDNA from RAG did not reveal any mutation. However, the CIITA protein was not detected. These data evidence a new type of defect in a MHC class II-defective tumor cell line, as we show here that the alteration in the RAG cells occurs downstream of C2ta transcription. The RAG mutation might therefore reside in the C2ta transcript nuclear export or translation, or in the stability of the CIITA protein.

Keywords: CIITA, MHC class II, tumor cell line, transcription


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
C. S. K. Yee, Y. Yao, P. Li, M. J. Klemsz, J. S. Blum, and C.-H. Chang
Cathepsin E: A Novel Target for Regulation by Class II Transactivator
J. Immunol., May 1, 2004; 172(9): 5528 - 5534.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.